"The thrill of victory and the agony of defeat."That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR Therapeutics (CRSP -9.01%) and Pfizer (PFE -1.88%) in 2023. CRISPR Therapeutics has enjoyed the thrill of victory, while Pfizer has experienced the agony of defeat.But which of these two biopharmaceutical stocks is the better pick for a new bull market? Motley Fool contributors Adria Cimino and Keith Speights make the argum ...